3 Growth Stocks to Fuel Your 2022 Financial Freedom_老虎社区_美港股上老虎

3 Growth Stocks to Fuel Your 2022 Financial Freedom

Motley Fool2021-12-13

2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

193

Tiongwee
·2021-12-13
Yes
回复
1
举报
Cherry23
·2021-12-13
Exciting💖
回复
2
举报
收起
- Cherry23:
  yes, it is🤑
  2021-12-28
  回复
  举报
- Tiongwee:
  Yesk
  2021-12-13
  回复
  举报
Chaishen
·2021-12-13
They hard sell you to buy, what’s next 😂
回复
3
举报
LCare
·2021-12-13
Ok
回复
1
举报
咸蛋超人POT
·2021-12-13
CHPT a contrary sentiment; pull and push effect due to their quality. AMRS go go go!
回复
点赞
举报
Jayous
·2021-12-13
Interesting…
回复
点赞
举报
vinnography
·2021-12-13
go
回复
1
举报
收起
- Jayous:
  Go to the moon🚀
  2021-12-13
  回复
  举报
男明星
·2021-12-13
🚀🚀🚀
回复
3
举报
jipbu
·2021-12-13
Ok
回复
5
举报
收起
- ortiz:
  ok
  2021-12-13
  回复
  举报
GG21
·2021-12-13
[Cool]
回复
2
举报
收起
- jipbu:
  ok
  2021-12-13
  回复
  举报
ivy888
·2021-12-13
Like
回复
2
举报
deadcow
·2021-12-13
ya
回复
5
举报
收起
- ivy888:
  ok
  2021-12-13
  回复
  举报
- Samwich:
  O
  2021-12-13
  回复
  举报
Sleepasaurus
·2021-12-13
Good
回复
5
举报
收起
- deadcow:
  ya
  2021-12-13
  回复
  举报
Raymondsj
·2021-12-13
L
回复
2
举报
Naknak
·2021-12-13
Ok
回复
1
举报
Pluto891
·2021-12-13
Tesla n so many EVs reported good results yet Charge point is not earning much . why?
回复
5
举报
收起
- doubleZ:
  Hahaha youre right.
  2021-12-13
  回复
  举报
Melvin888
·2021-12-13
Charge point
回复
4
举报
收起
- Melvin888:
  Ya
  2021-12-13
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2190467769?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-13 11:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2190467769","market":"us","top_or_hot":-1,"title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","media":"Motley Fool","content":"<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","article_id":"2190467769","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","pubTimestamp":1639367630,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","CHPT":"ChargePoint Holdings Inc.","CAGR":"California Grapes International, Inc.","AMRS":"阿米瑞斯","BK4109":"特种化学制品","BK4542":"充电桩","BK4096":"电气部件与设备","BK4093":"化肥与农用药剂","CTVA":"Corteva, Inc."},"translate_title":"3只成长股为你2022年的财务自由加油","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRS":0.9,"CAGR":0.9,"CHPT":0.9,"CTVA":0.9},"content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":604204191,"gmtCreate":1639398043403,"gmtModify":1639398044606,"author":{"id":"3573775111920367","authorId":"3573775111920367","name":"Tiongwee","avatar":"https://static.tigerbbs.com/e90910e406e67c77f42e225b16b69020","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604204191","repostId":2190467769,"repostType":2,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":604647649,"gmtCreate":1639394121910,"gmtModify":1639394189481,"author":{"id":"4091238990199980","authorId":"4091238990199980","name":"Cherry23","avatar":"https://static.tigerbbs.com/fda4d6f2aa8bb4fb772b7ea537dd78a7","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Exciting💖","listText":"Exciting💖","text":"Exciting💖","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604647649","repostId":2190467769,"repostType":4,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7127312,"gmtCreate":1640688862278,"gmtModify":1640688862436,"authorId":4091238990199980,"author":{"id":4091238990199980,"authorId":4091238990199980,"name":"Cherry23","avatar":"https://static.tigerbbs.com/fda4d6f2aa8bb4fb772b7ea537dd78a7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":604647649,"type":1,"supId":6964393,"prevId":0,"content":"yes, it is🤑","text":"yes, it is🤑","html":"yes, it is🤑"},{"id":6964393,"gmtCreate":1639398054992,"gmtModify":1639398055088,"authorId":3573775111920367,"author":{"id":3573775111920367,"authorId":3573775111920367,"name":"Tiongwee","avatar":"https://static.tigerbbs.com/e90910e406e67c77f42e225b16b69020","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":604647649,"type":1,"supId":0,"prevId":0,"content":"Yesk","text":"Yesk","html":"Yesk"}],"langContent":"CN"},{"id":604642570,"gmtCreate":1639393772508,"gmtModify":1639394158406,"author":{"id":"3575102877976288","authorId":"3575102877976288","name":"Chaishen","avatar":"https://static.tigerbbs.com/b8bb167c6f990b4a02d66313039eb021","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"They hard sell you to buy, what’s next 😂&nbsp;","listText":"They hard sell you to buy, what’s next 😂&nbsp;","text":"They hard sell you to buy, what’s next 😂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604642570","repostId":2190467769,"repostType":2,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":604646293,"gmtCreate":1639393556745,"gmtModify":1639394150911,"author":{"id":"4099126036711530","authorId":"4099126036711530","name":"LCare","avatar":"https://static.tigerbbs.com/ef5791162e4724ba08e570bfc4bd79fd","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604646293","repostId":2190467769,"repostType":2,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":604648141,"gmtCreate":1639393336330,"gmtModify":1639394147844,"author":{"id":"3575010783330312","authorId":"3575010783330312","name":"咸蛋超人POT","avatar":"https://static.tigerbbs.com/ffe12d12ec49236cc05d807be8348dc0","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"CHPT a contrary sentiment; pull and push effect due to their quality.&nbsp; AMRS go go go!","listText":"CHPT a contrary sentiment; pull and push effect due to their quality.&nbsp; AMRS go go go!","text":"CHPT a contrary sentiment; pull and push effect due to their quality. AMRS go go go!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604648141","repostId":2190467769,"repostType":4,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":604641650,"gmtCreate":1639393248674,"gmtModify":1639393683425,"author":{"id":"3574857997483310","authorId":"3574857997483310","name":"Jayous","avatar":"https://static.tigerbbs.com/b8d0899088d0307c3504bb6203af38b8","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Interesting…","listText":"Interesting…","text":"Interesting…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604641650","repostId":2190467769,"repostType":2,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":604641851,"gmtCreate":1639393236779,"gmtModify":1639393683345,"author":{"id":"3582454731376352","authorId":"3582454731376352","name":"vinnography","avatar":"https://static.tigerbbs.com/b98379fe841af901588fb3942d07aed4","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"go","listText":"go","text":"go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604641851","repostId":2190467769,"repostType":2,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6963908,"gmtCreate":1639393286029,"gmtModify":1639393286063,"authorId":3574857997483310,"author":{"id":3574857997483310,"authorId":3574857997483310,"name":"Jayous","avatar":"https://static.tigerbbs.com/b8d0899088d0307c3504bb6203af38b8","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":604641851,"type":1,"supId":0,"prevId":0,"content":"Go to the moon🚀","text":"Go to the moon🚀","html":"Go to the moon🚀"}],"langContent":"CN"},{"id":604851217,"gmtCreate":1639374411032,"gmtModify":1639374411032,"author":{"id":"4101597725397040","authorId":"4101597725397040","name":"男明星","avatar":"https://static.tigerbbs.com/30b6decb3d47ffa85fe289541ad687d4","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"🚀🚀🚀","listText":"🚀🚀🚀","text":"🚀🚀🚀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604851217","repostId":2190467769,"repostType":4,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":604827516,"gmtCreate":1639373766650,"gmtModify":1639373766650,"author":{"id":"3581990837361530","authorId":"3581990837361530","name":"jipbu","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604827516","repostId":2190467769,"repostType":4,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6961638,"gmtCreate":1639374193093,"gmtModify":1639374193187,"authorId":3569050312475646,"author":{"id":3569050312475646,"authorId":3569050312475646,"name":"ortiz","avatar":"https://static.tigerbbs.com/2c34fed4afb9aa375ead5a73c050caef","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":604827516,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":604828178,"gmtCreate":1639372967361,"gmtModify":1639372967549,"author":{"id":"3578365762999468","authorId":"3578365762999468","name":"GG21","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"[Cool]&nbsp;","listText":"[Cool]&nbsp;","text":"[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604828178","repostId":2190467769,"repostType":4,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6961578,"gmtCreate":1639373774267,"gmtModify":1639373774304,"authorId":3581990837361530,"author":{"id":3581990837361530,"authorId":3581990837361530,"name":"jipbu","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":604828178,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":604828097,"gmtCreate":1639372889665,"gmtModify":1639372890680,"author":{"id":"3579641974902127","authorId":"3579641974902127","name":"ivy888","avatar":"https://static.tigerbbs.com/10358949b7fc96b011ec29ca7fd9c9a4","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604828097","repostId":2190467769,"repostType":4,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":604863320,"gmtCreate":1639371032563,"gmtModify":1639371032853,"author":{"id":"3579085067033099","authorId":"3579085067033099","name":"deadcow","avatar":"https://static.tigerbbs.com/b73e551a33ab83c745d06a9d890b1f93","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"ya","listText":"ya","text":"ya","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604863320","repostId":2190467769,"repostType":4,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6961459,"gmtCreate":1639372897430,"gmtModify":1639372897531,"authorId":3579641974902127,"author":{"id":3579641974902127,"authorId":3579641974902127,"name":"ivy888","avatar":"https://static.tigerbbs.com/10358949b7fc96b011ec29ca7fd9c9a4","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":604863320,"type":1,"supId":6961427,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":6961427,"gmtCreate":1639372751605,"gmtModify":1639372751701,"authorId":3575000650579772,"author":{"id":3575000650579772,"authorId":3575000650579772,"name":"Samwich","avatar":"https://static.tigerbbs.com/333bbe08da61ec501a2da43a65e31462","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":604863320,"type":1,"supId":0,"prevId":0,"content":"O","text":"O","html":"O"}],"langContent":"CN"},{"id":604863908,"gmtCreate":1639371027580,"gmtModify":1639371027765,"author":{"id":"3576109542283442","authorId":"3576109542283442","name":"Sleepasaurus","avatar":"https://static.tigerbbs.com/8c77a73bd8036f3ff216362f4628956a","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604863908","repostId":2190467769,"repostType":4,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6961172,"gmtCreate":1639371041182,"gmtModify":1639371041215,"authorId":3579085067033099,"author":{"id":3579085067033099,"authorId":3579085067033099,"name":"deadcow","avatar":"https://static.tigerbbs.com/b73e551a33ab83c745d06a9d890b1f93","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":604863908,"type":1,"supId":0,"prevId":0,"content":"y<u>a</u>","text":"y<u>a</u>","html":"y<u>a</u>"}],"langContent":"CN"},{"id":604884516,"gmtCreate":1639370739626,"gmtModify":1639370739719,"author":{"id":"3569352578277592","authorId":"3569352578277592","name":"Raymondsj","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"L","listText":"L","text":"L","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604884516","repostId":2190467769,"repostType":4,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":604885629,"gmtCreate":1639370463892,"gmtModify":1639371615873,"author":{"id":"4102131234533630","authorId":"4102131234533630","name":"Naknak","avatar":"https://static.tigerbbs.com/ace53ebcca76826c32189de91a930c1d","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604885629","repostId":2190467769,"repostType":4,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":604881237,"gmtCreate":1639369905189,"gmtModify":1639370160453,"author":{"id":"3581937910767045","authorId":"3581937910767045","name":"Pluto891","avatar":"https://static.tigerbbs.com/c9963f2ef3d3ad2aff28340461d3d6d0","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Tesla n so many EVs reported good results yet Charge point is not earning much&nbsp;. why?","listText":"Tesla n so many EVs reported good results yet Charge point is not earning much&nbsp;. why?","text":"Tesla n so many EVs reported good results yet Charge point is not earning much . why?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604881237","repostId":2190467769,"repostType":4,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6965263,"gmtCreate":1639403074476,"gmtModify":1639403074577,"authorId":3556582009315298,"author":{"id":3556582009315298,"authorId":3556582009315298,"name":"doubleZ","avatar":"https://static.tigerbbs.com/90d125f550abadf09dc8f4dace09e00c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":604881237,"type":1,"supId":0,"prevId":0,"content":"Hahaha youre right. ","text":"Hahaha youre right. ","html":"Hahaha youre right. "}],"langContent":"CN"},{"id":604880338,"gmtCreate":1639369595108,"gmtModify":1639369595364,"author":{"id":"3577938728188071","authorId":"3577938728188071","name":"Melvin888","avatar":"https://static.tigerbbs.com/1f7e36200d6d8c6159f6d35c041d8e3e","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Charge point&nbsp;","listText":"Charge point&nbsp;","text":"Charge point","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604880338","repostId":2190467769,"repostType":4,"repost":{"id":"2190467769","pubTimestamp":1639367630,"share":"https://www.laohu8.com/m/news/2190467769?lang=&edition=full","pubTime":"2021-12-13 11:53","market":"us","language":"en","title":"3 Growth Stocks to Fuel Your 2022 Financial Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2190467769","media":"Motley Fool","summary":"This basket of industrial and electric vehicle stocks is primed to pole vault your portfolio.","content":"<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.</p>\n<p><b>Corteva</b> (NYSE:CTVA), <b>Amyris</b> (NASDAQ:AMRS), and <b>ChargePoint Holdings</b> (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F656760%2Fgettyimages-1304258192.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Investor confidence is growing in the agriscience company</h2>\n<p><b>Lee Samaha (Corteva):</b> After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner <b>Bayer</b>, <b>BASF</b>, and <b>Syngenta</b>.</p>\n<p>The potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.</p>\n<p>The good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.</p>\n<p>As such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.</p>\n<h2>Supply chain woes knocked this stock down, but it's poised to get back up again</h2>\n<p><b>Scott Levine (Amyris): </b>Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.</p>\n<p>One of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"</p>\n<p>The company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.</p>\n<p>As companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.</p>\n<h2>This EV charging stock is off to the races</h2>\n<p><b>Daniel Foelber (ChargePoint Holdings): </b>America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.</p>\n<p>The growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.</p>\n<p>Although still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks to Fuel Your 2022 Financial Freedom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks to Fuel Your 2022 Financial Freedom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 11:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4551":"寇图资本持仓","CAGR":"California Grapes International, Inc.","BK4535":"淡马锡持仓","CTVA":"Corteva, Inc.","CHPT":"ChargePoint Holdings Inc.","AMRS":"阿米瑞斯","BK4096":"电气部件与设备","BK4542":"充电桩","BK4093":"化肥与农用药剂","BK4109":"特种化学制品"},"source_url":"https://www.fool.com/investing/2021/12/12/3-growth-stocks-to-fuel-your-2022-financial-freedo/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190467769","content_text":"2021 is nearly over, and that means it's time to plan for 2022. With stocks, crypto, real estate, and several other asset classes hovering around all-time highs, there's certainly a lot to be grateful for this year. However, those gains have come and gone. The challenge now is finding the best places to invest for 2022 and beyond.\nCorteva (NYSE:CTVA), Amyris (NASDAQ:AMRS), and ChargePoint Holdings (NYSE:CHPT) are three growth stocks that could bring you closer to securing financial freedom. Here's what makes each a great buy now.\nImage source: Getty Images.\nInvestor confidence is growing in the agriscience company\nLee Samaha (Corteva): After a few years of questionable performance, it looks like Corteva is starting to realize the potential in its business. The company was created out of the DowDuPont merger and subsequent breakup. As such, it's the leading U.S. player in seed and crop protection, competing with international companies such as Monsanto owner Bayer, BASF, and Syngenta.\nThe potential in the business lies in the expectation that Corteva can improve productivity and catch up to the kind of margins enjoyed by its peers. Among the ways it can enhance margin is by selling more of its products under its patents. This means Corteva will lower the share of revenue it pays in royalty costs to other companies, and Corteva's profit margin will go up.\nThe good news is the company is making progress on all fronts. For example, management recently reaffirmed its target of $2.8 billion to $3.1 billion in adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in 2022, rising from $2.5 billion to $2.6 billion in 2021. Moreover, management noted that the adoption rate of its Enlist (seed and crop protection) system was better than it had expected in 2021. In addition, there's a strong pipeline of other products under Corteva's patents coming through in the next few years.\nAs such, a combination of mid-single-digit revenue growth and margin expansion promises to deliver double-digit earnings growth over the medium term for Corteva.\nSupply chain woes knocked this stock down, but it's poised to get back up again\nScott Levine (Amyris): Shares of synthetic biology specialist Amyris have both thrilled and devastated investors in 2021. While the stock skyrocketed more than 209% through the first three months of the year, it came back to earth in the second half -- particularly last month, when it fell 54%. Although it's the bears who are most interested in the stock at the moment, the company has several catalysts on the horizon in 2022 that could propel it considerably higher.\nOne of the primary reasons for the stock's sell-off last month was concern related to supply chain headwinds facing Amyris and fear that they'd continue to plague the company in the coming months. But Amyris is working to shore up its supply chain, developing two facilities in Brazil and Nevada, both of which are expected to commence operations in the first half of 2022. According to John Melo, the company's CEO, the importance of the two facilities will have a material impact on its finances. On the company's third-quarter conference call, Melo said, \"These facilities will not only provide us much more resilience on the supply chain, they will also reduce our operating costs significantly and improve our gross margin by about 1,000 basis points.\"\nThe company's growth, however, transcends an improvement in its gross margin as management forecasts revenue will rise to over $500 million in 2022 and $1 billion in 2023. For some perspective, Amyris reported $173 million on the top line in 2020, and it has booked sales of $357 million over the past 12 months. Looking toward the bottom of the income statement, investors can expect the company to report positive earnings before interest, taxes, depreciation, and amortization (EBITDA) -- a feat it last achieved in 2014.\nAs companies look to source their products with sustainable ingredients, Amyris and its line of synbio-based products will likely become increasingly appealing. For forward-looking investors who have the patience to let this growth story play out, the stock's recent sell-off offers a great opportunity to pick up shares on the cheap, leaving more money available to splurge on presents for friends and loved ones.\nThis EV charging stock is off to the races\nDaniel Foelber (ChargePoint Holdings): America's largest electric vehicle (EV) charging infrastructure company, ChargePoint, reported third-quarter fiscal year 2022 earnings on Tuesday that exceeded expectations. After generating $65 million in revenue, ChargePoint now expects to earn between $73 million and $78 million in fourth-quarter revenue, bringing its full-year sales to between $235 million and $240 million. If it hits its target, ChargePoint would have grown its top line by 63% compared to last year. For context, consider that ChargePoint earned $146 million in revenue in fiscal year 2021 and $144.5 million in fiscal year 2020 revenue.\nThe growth rate is impressive, but even if ChargePoint hits its revenue target it would still have a price-to-sales ratio of 28.7, which is more expensive than some of the market's hottest growth stocks. However, COVID-19 stunted its fiscal year 2021 growth and the company could now be off to the races now that EV investment is increasing. ChargePoint expects its rise to be directly proportional to the growth rate of U.S. passenger EV sales. Between 2020 to 2026, ChargePoint expects U.S. passenger EV sales to rise at a compound annual growth rate (CAGR) of 41% as more affordable EVs come on stream and consumer demand for EVs increases.\nAlthough still a long way from profitability, ChargePoint is an excellent catch-all way to expose your portfolio to the growth of EVs without having to risk picking a particular automaker to win out.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6960944,"gmtCreate":1639369602526,"gmtModify":1639369602616,"authorId":3577938728188071,"author":{"id":3577938728188071,"authorId":3577938728188071,"name":"Melvin888","avatar":"https://static.tigerbbs.com/1f7e36200d6d8c6159f6d35c041d8e3e","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":604880338,"type":1,"supId":0,"prevId":0,"content":"Ya","text":"Ya","html":"Ya"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":193,"commentSize":0,"repostSize":0,"favoriteSize":5,"likeStatus":false,"favoriteStatus":false}}